Digital Aria Co Ltd (115450) - Total Liabilities

Latest as of March 2026: ₩53.34 Billion KRW ≈ $36.15 Million USD

Based on the latest financial reports, Digital Aria Co Ltd (115450) has total liabilities worth ₩53.34 Billion KRW (≈ $36.15 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 115450 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

Digital Aria Co Ltd - Total Liabilities Trend (2011–2025)

This chart illustrates how Digital Aria Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Digital Aria Co Ltd (115450) total assets.

Digital Aria Co Ltd Competitors by Total Liabilities

The table below lists competitors of Digital Aria Co Ltd ranked by their total liabilities.

Company Country Total Liabilities
Dwi Guna Laksana Tbk PT
JK:DWGL
Indonesia Rp1.66 Trillion
Cornish Metals Inc.
V:CUSN
Canada CA$15.90 Million
Yeong Hwa Meta
KO:012280
Korea ₩154.55 Billion
Méliuz S.A
SA:CASH3
Brazil R$91.93 Million
John Hancock Income Securities Closed Fund
NYSE:JHS
USA $93.25 Million
Mnc Investama Tbk
JK:BHIT
Indonesia Rp33.74 Trillion
NOVAREX Co.Ltd
KQ:194700
Korea ₩112.55 Billion
SAI SILKS (KALAMANDIR) LIMITED
NSE:KALAMANDIR
India Rs5.88 Billion

Liability Composition Analysis (2011–2025)

This chart breaks down Digital Aria Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Digital Aria Co Ltd (115450) balance sheet quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.34 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.35 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.23 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Digital Aria Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Digital Aria Co Ltd (2011–2025)

The table below shows the annual total liabilities of Digital Aria Co Ltd from 2011 to 2025.

Year Total Liabilities Change
2025-12-31 ₩54.79 Billion
≈ $37.13 Million
-12.09%
2024-12-31 ₩62.33 Billion
≈ $42.24 Million
+112.90%
2023-12-31 ₩29.28 Billion
≈ $19.84 Million
-58.73%
2022-12-31 ₩70.94 Billion
≈ $48.07 Million
-0.14%
2021-12-31 ₩71.03 Billion
≈ $48.14 Million
+117.99%
2020-12-31 ₩32.58 Billion
≈ $22.08 Million
-56.89%
2019-12-31 ₩75.58 Billion
≈ $51.22 Million
+93.83%
2018-12-31 ₩38.99 Billion
≈ $26.43 Million
+60.68%
2017-12-31 ₩24.27 Billion
≈ $16.45 Million
+36.58%
2016-12-31 ₩17.77 Billion
≈ $12.04 Million
-12.31%
2015-12-31 ₩20.26 Billion
≈ $13.73 Million
-43.71%
2014-12-31 ₩36.00 Billion
≈ $24.40 Million
+36.85%
2013-12-31 ₩26.31 Billion
≈ $17.83 Million
-34.61%
2012-12-31 ₩40.23 Billion
≈ $27.26 Million
-8.26%
2011-12-31 ₩43.85 Billion
≈ $29.72 Million
--

About Digital Aria Co Ltd

KQ:115450 Korea Biotechnology
Market Cap
$122.47 Million
₩180.72 Billion KRW
Market Cap Rank
#18519 Global
#843 in Korea
Share Price
₩2050.00
Change (1 day)
+0.74%
52-Week Range
₩1451.00 - ₩3980.00
All Time High
₩25764.90
About

HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrica… Read more